MEK inhibitors and DA‐Raf, a dominant‐negative antagonist of the Ras–ERK pathway, prevent the migration and invasion of KRAS‐mutant cancer cells - Matsuda, Aoi; Masuzawa, Ryuichi; Takahashi, Kazuya; Takano, Kazunori; Endo, Takeshi (Cytoskeleton, 2025)
Keywords: Adenocarcinoma; Antineoplastic drugs; Cancer; cancer cell; Cell Line, Tumor; Cell migration; Cell Movement - drug effects; Cell proliferation; Cell survival; Colorectal cancer; Colorectal carcinoma; Extracellular signal-regulated kinase; Humans; Inhibitor drugs; invasion; K-Ras protein; Kinases; Lung cancer; Lung carcinoma; MAP Kinase Signaling System - drug effects; MEK inhibitors; Metabolic pathways; Metastases; metastasis; migration; Mutants; Mutation; Neoplasm Invasiveness; Pancreatic cancer; Pancreatic carcinoma; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins A-raf - genetics; Proto-Oncogene Proteins A-raf - metabolism; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras) - genetics; Proto-Oncogene Proteins p21(ras) - metabolism; Raf protein; Ras protein; Ras–ERK pathway; Tumor cell lines; Tumor suppressor genes; Tumorigenesis; migration; Ras–ERK pathway; cancer cell; invasion; metastasis